NEXT GENERATION CANCER MODELS (NON CMDC) MOLECULAR CHARACTERIZATION AND CLINICAL DATA COLLECTION

该项目的目的是资助可能没有完整注释的分布模型的分子表征（例如，母肿瘤和有时正常可能缺失），将增加具有15倍全基因组测序、150倍全外显子组测序、转录组测序和表观遗传学表征的模型数量，即，模型将具有与CMDC生成的模型相同的可用数据。 对于有临床数据可用的模型，也将收集（在不同机制下收集）。 这将增加可用于大规模筛查研究的模型数量，通过开发的分销渠道增加肿瘤亚型的数量，并以适度的投资扩大NCI提供给社区的模型数量。 据估计，通过这一管道将增加多达200个非政府协调机制。

The purpose of the project is to fund the molecular characterization of models for distribution that probably would not have as complete annotation (e.g. the parent tumor and sometime normal could be missing), would increase the number of models that would have whole genome sequencing at 15X, whole exome sequencing at 150X, transcriptome sequencing and epigenetic characterization, i.e. the models would have the same data as are available for CMDC generated models. For the models for which clinical data is available, it would be collected as well (collected under a different mechanism). This would increase the number of models available for large scale screening studies, increase the number of tumor subtypes available through the developed distribution pipeline and for a modest investment enlarge the number of models that NCI provides to the community. It is estimated that up to 200 NGCMs would be added through this pipeline.